Prostate Cancer | Specialty

Urologists Must Keep Up With Advances and Stay at the Helm

June 20th 2019

Over the past 5 years, the need for urologists to continue to be the leaders— the quarterbacks—in the diagnosis and management of prostate cancer has often been discussed. History will attest to urologists' success in leading this charge.

Urology Austin Innovates to Deliver High-Quality Care

June 20th 2019

The decision to expand a practice comes with great financial cost and administrative effort. For Urology Austin, however, the benefits for their patients have outweighed the challenges of such growth.

Dr. Mouw on the Role of Radiation Therapy in Prostate Cancer

June 20th 2019

Kent W. Mouw, MD, PhD, co-director, Bladder Cancer Center, assistant professor, Radiation Oncology, Harvard Medical School, Dana-Farber Cancer Institute, discusses the role of radiation therapy in prostate cancer.

Dr. Lee on Inclusion Criteria of the ARAMIS, SPARTAN, and PROSPER Trials in M0CRPC

June 20th 2019

Richard (Rick) JaeBong Lee, MD, PhD, medical oncologist at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School, discusses inclusion criteria of the phase III ARAMIS, SPARTAN, and PROSPER trials in nonmetastatic castration-resistant prostate cancer (M0CRPC).

PSMA Emerges as Versatile Target in Prostate Cancer and Beyond

June 19th 2019

Named the medical invention of the Year by TIME magazine at the turn of the millennium, positron emission tomography/computed tomography has changed the landscape of cancer diagnosis, facilitating earlier detection and more accurate staging of a range of tumor types.

Dr. Einstein on Novel Imaging Tools in Prostate Cancer

June 19th 2019

David J. Einstein, MD, genitourinary medical oncologist, Beth Israel Deaconess Medical Center, discusses novel imaging tools used in prostate cancer.

Dr. McGregor on Guidelines Regarding ADT-Associated Cardiac AEs in Prostate Cancer

June 19th 2019

Pei-Chun McGregor, MD, cardio-oncologist and director of Ambulatory Cardiology at VA Boston Healthcare System, instructor in medicine, Brigham and Women’s Hospital, discusses guidelines regarding androgen deprivation therapy (ADT)-associated cardiac adverse events (AEs) in prostate cancer.

Dr. Caffo Discusses Enzalutamide/Docetaxel Combination in Frontline mCRPC

June 17th 2019

Orazio Caffo, MD, director of medical oncology at the Santa Chiara Hospital in Trento, Italy, discusses enzalutamide plus docetaxel combination for the frontline treatment of metastatic castration-resistant prostate cancer.

Immune System Agents May Move Into Earlier Settings in GU Cancers

June 13th 2019

Over the past 5 years, medical oncologists have witnessed the revolutionary impact of immunotherapy on patients with advanced urologic malignancies. Over the next 5 years, these therapies likely will similarly transform urologic surgical care.

SM-88 Shows Efficacy in Pancreatic, Prostate Cancers

June 13th 2019

Having a late-stage treatment for pancreatic cancer that avoids many of the adverse events associated with chemotherapy would be a boon for patients.

Dr. Fizazi Discusses Updated Data With Darolutamide in CRPC

June 13th 2019

Karim Fizazi, MD, PhD, head, Department of Cancer Medicine, Gustave Roussy Cancer Center, Villejuif, France, discusses updated data with darolutamide in castration-resistant prostate cancer.

Dr. Choudhury on the Importance of Volume Status in Metastatic Prostate Cancer

June 12th 2019

Atish D. Choudhury, MD, PhD, co-director of the Prostate Cancer Center, senior physician, Dana-Farber Cancer Institute, and instructor in medicine, Harvard Medical School, discusses the importance of volume status in prostate cancer.

Dr. Dorff Discusses the Use of PARP Inhibitors in Prostate Cancer

June 11th 2019

Tanya B. Dorff, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research, and head of the genitourinary cancers program at City of Hope, discusses the use of PARP inhibitors in prostate cancer.

Dr. Lee on the ARAMIS Trial in M0CRPC

June 7th 2019

Richard (Rick) JaeBong Lee, MD, PhD, medical oncologist at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School, discusses results from the phase III ARAMIS trial in nonmetastatic castration-resistant prostate cancer (M0CRPC).

Dr. Yu on the Drawbacks of Radiation Therapy in Prostate Cancer

June 6th 2019

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses drawbacks of radiation therapy in prostate cancer.

Dr. Sweeney on the Phase III ENZAMET Trial in Metastatic Hormone-Sensitive Prostate Cancer

June 3rd 2019

Christopher Sweeney, MBBS, medical oncologist at the Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, discusses results of the phase III ENZAMET trial, which looked at standard therapy with or without enzalutamide as a treatment for patients with metastatic hormone-sensitive prostate cancer.

Enzalutamide Increases Survival in mHSPC Over Other Anti-Androgens

June 2nd 2019

Almost 80% of men with metastatic hormone-sensitive prostate cancer treated with enzalutamide plus standard of care (SOC) were alive after 3 years compared with 72% of patients who received a different non-steroidal anti-androgen plus SOC.

ASCO 2019: Dr. Plimack Highlights Practice-Changing Data for Genitourinary Cancers

June 2nd 2019

ASCO 2019: Dr. Ferris Discusses the Latest Data in Head and Neck Cancer

June 2nd 2019

Dr. Tolaney Highlights New Breast Cancer Combination Therapies

June 2nd 2019